(NYSE American: VNRX) Lands Sole Biomarker Role In French Government Sepsis Program

Monday's profile popped at the get-go.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: VNRX) Lands Sole Biomarker Role In French Government Sepsis Program *Get Our Updates Faster—Tap Here To Receive SMS Alerts* October 26th Greetings, Friend! Monday's profile popped at the get-go. Surging $.75 from an open of $4.30 to a high of $5.05, it ran approx. 17% intraday. As that move was unfolding, something else caught our attention... Picture the emergency department at Ambroise Paré Hospital outside Paris. A patient arrives with a suspected infection. Will they slide into sepsis, or can they safely go home? Under a program that officially launched in September, that call may now be informed by a single blood marker supplied by VolitionRx Limited (NYSE American: VNRX). The DETECSEPS project is funded with approx. €6.3Mn (~$7.3Mn) from the French government and was initiated by IHU SEPSIS, a center dedicated entirely to fighting sepsis. Volition’s Nu.Q® NETs assay was selected as the program’s sole biomarker. It runs on the IDS i10® automated analyzer from IDS France, part of Revvity, with results available within one hour. The stakes are hard to overstate. The consortium cites roughly 166Mn sepsis cases worldwide each year, plus nearly 57,000 sepsis deaths annually in France alone. A peer-reviewed paper in Critical Care Medicine found Nu.Q® NETs H3.1 independently predicted 28-day mortality and the need for kidney replacement therapy in sepsis and septic shock patients. Volition spotlighted that study in its August corporate update, alongside an independent editorial in the same journal. The balance sheet got attention too. Volition retired the outstanding balance of its $7.5Mn senior secured convertible note in cash, more than eight months ahead of its May 2027 maturity. Management said the move prevents further potential dilution tied to that note. Then there is cancer. Presenting at the ESMO MAP conference in London, the company reported 49 of 49 cancers detected in a first Capture-Seq™ cohort with no false positives. A separate blinded validation cohort showed 95% detection of stage I and II cancers at 95% specificity. Behind The Scenes: What Management Told Wall Street Replay the second quarter 2026 earnings call and the tone is disciplined. VNRX CEO Cameron Reynolds and CFO Terig Hughes walked through a quarter where operating expenses fell 32% to approx. $4.6Mn from $6.7Mn, helped by a 27% headcount reduction. First-half revenue reached $1.4Mn, up 112% year over year. Volition said its finger-prick lateral flow prototype showed roughly 90% correlation with its CE-marked automated assay in critically ill sepsis patients. Management also noted it is supplying Mayo Clinic with an IDS i10® analyzer, building on a trauma study published in Shock. For pets, the feline lymphoma prototype detected 86% of cases at 97% specificity. Volition expects peer-reviewed publication of that study to trigger a $5Mn contractual milestone payment. The Pivot: From Test Developer To Licensing Platform Volition’s strategic shift is now clear. Rather than build a global sales force, the company is pursuing licensing deals that may bring upfront milestone payments, royalties, and recurring revenue. It confirms active discussions with more than a dozen leading diagnostic and liquid biopsy companies. Existing partners give that plan weight. Per the company’s latest quarterly filing, IDEXX launched a Nu.Q® canine cancer test in 2023, Fujifilm Vet Systems runs an automated version in Japan, and Hologic Diagenode co-markets Nu.Q® Discover services. Most recently, Volition transferred its Nu.Q® NETs assay onto the platform of Tokyo-listed Sysmex Corporation, ahead of an anticipated broader agreement. The company pegs its combined annualized addressable markets at more than $27Bn, led by an estimated $23Bn for Capture-Seq™ cancer detection. About VolitionRx Limited Volition is a multi-national epigenetics company headquartered in Henderson, Nevada, with R&D centered in Belgium. Its Nucleosomics™ platform measures nucleosomes, the DNA-protein building blocks whose levels and modifications shift with cancer, sepsis, and other diseases. The portfolio spans five pillars. Nu.Q® NETs is a CE-marked test for NETosis-related conditions such as sepsis. Nu.Q® Vet is a canine cancer test available in more than 20 countries. Nu.Q® Discover supplies epigenetic profiling services and kits to pharmaceutical and academic teams. Nu.Q® Cancer includes a lung cancer test headed for a reimbursement submission in France with Hospices Civils de Lyon. Capture-Seq™, backed by its first peer-reviewed paper, is the newest liquid biopsy method. Sources: VolitionRx releases (Aug. 26th and Sept. 10th) and the Volition.com product page. 7 Potential Catalysts Send (NYSE American: VNRX) To The Top Of Our Watchlist #1. Government-Funded Sepsis Program Now Live In French Hospitals. France’s approx. €6.3Mn DETECSEPS program chose Nu.Q® NETs as its sole biomarker, giving (VNRX) a potential real-world showcase in emergency care. #2. A $5Mn Feline Milestone Awaits Peer-Reviewed Publication. Management expects publication of its feline lymphoma study to unlock this contractual payment, a potentially meaningful non-dilutive inflow for (VNRX). #3. Licensing Talks Underway With More Than A Dozen Diagnostic Leaders. Any signed agreement could potentially add upfront payments and royalties, and (VNRX) has already moved its NETs assay onto the Sysmex platform. #4. Lung Cancer Reimbursement Submission Targeted In France By Year-End. Management calls reimbursement the next step toward routine clinical use of Nu.Q®, though approval for (VNRX) is not assured. #5. Low Float Profile Could Create The Potential For Heightened Volatility. Recent share data lists a float of approx. 12.53Mn shares for (VNRX), a low float setup where the potential for heightened volatility may be significant. #6. Early Note Payoff Signals Focus On Balance Sheet Repair. By retiring its $7.5Mn note early in cash, (VNRX) removed a potential source of dilution, and management says further debt reduction is a top priority. #7. Third-Quarter Update Expected Around November 12th, 2026. The estimated report date gives (VNRX) a potential stage to update on DETECSEPS, licensing talks and the feline milestone. Final Thoughts VolitionRx Limited (NYSE American: VNRX) is still an early commercial story. What has changed is the evidence and the company it keeps. A government-backed sepsis program, a growing body of peer-reviewed data, a debt payoff and a $5Mn milestone in waiting all point to a company working to turn science into revenue. With third-quarter results on deck, VNRX belongs on your radar. Coverage is now initiated on VolitionRx Limited (NYSE American: VNRX). Updates will be out soon. Stay tuned for more. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 10/26/2026 and ending on 10/27/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid thirty nine thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/vnrx-zly0g/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice